Nanotherapeutics for Neurological Disorders

Author(s): Sanjula Baboota, Javed Ali

Journal Name: Current Pharmaceutical Design

Volume 26 , Issue 19 , 2020


Become EABM
Become Reviewer
Call for Editor

[1]
A. Manish,, A. Bhawana,, A. Anupriya,. et al Cold atmospheric plasma as a novel therapeutic tool for the treatment of brain cancer. Curr Pharm Des 2020; 26(19): 2195-206.
[2]
N.C Eemaan,, PDK Pierre,, EC Yahya,, C du T Lisa,, P Viness. Carbon dots as nanotherapeutics for biomedical application. Curr Pharm Des 2020; 26(19): 2207-21.
[3]
Md Shadab,, K Shahid,, R.S Sanggetha,. et alCurrent status and challenges in rotigotine delivery. Curr Pharm Des 2020; 26(19): 2222-32.
[4]
G Bapi,, CR Davinaa,, P Manisha,, K Prashant,, AK Santosh,, C Hira. Nose to brain delivery of nanocarriers towards attenuation of demented condition. Curr Pharm Des 2020; 26(19): 2233-46.
[5]
S. Surbhi,, D Shweta. Neuropsychological disorders and their nanocarriers. Curr Pharm Des 2020; 26(19): 2247-56.
[6]
D Anmol, Narang. RS, KN Jasjeet. Recent advances in nanotherapeutic interventions for the treatment of alzheimer’s disease. Curr Pharm Des 2020; 26(19): 2257-79.
[7]
A Nidhi,, Q Zufika,, R Saleha,, B Sanjula,, A Javed. Orally administered nanotherapeutics for parkinson’s disease: an old delivery system yet more acceptable. Curr Pharm Des 2020; 26(19): 2280-90.
[8]
M Saurabh,, UA Muhammad,, FQ Farheen,. et alLigand conjugated targeted nanotherapeutics for treatment of neurological disorders. Curr Pharm Des 2020; 26(19): 2291-305.


free to download

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 26
ISSUE: 19
Year: 2020
Published on: 17 June, 2020
Page: [2193 - 2194]
Pages: 2
DOI: 10.2174/138161282619200520074049

Article Metrics

PDF: 20
HTML: 2